Genomic Vision

Financial Information for the Third Quarter of 2023

Regulatory News:

Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announced its revenue and cash position for the third quarter ended on September 30, 2023¹.

Revenues for the first 9 months and 3^rd quarter 2023

		9 months				Third quarter
(In € thousands – IFRS standards)		2023	2022	∆		2023	2022	∆%
Total revenue from sales		853	768	+11%		260	257	n.s.
Other revenue		350	348	n.s.		117	116	n.s.
Total revenue from activity		1203	1116	+8%		377	373	n.s.

Total revenue from activities reached €1 203 thousand in the third quarter ending September 30, 2023, reflecting a 11% increase compared to the same period in the previous year. The revenue include:

• sales of products and services of €853 thousand, up 11% compared with 2022. This is explained by good on-going sales performance particularly in RCA (Replication Combing Assay) services.
• other revenue of €350 thousand during the third quarter ended September 30, 2023, related to a Research Tax Credit.

Financial structure at September 30, 2023